Description: Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.
Home Page: www.genmab.com
Carl Jacobsens Vej 30
Copenhagen,
2500
Denmark
Phone:
45 70 20 27 28
Officers
| Name | Title |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO |
| Mr. Anthony Pagano CPA | Executive VP & CFO |
| Ms. Birgitte Stephensen M.Sc. | Executive VP & Chief Legal Officer |
| Mr. Christopher Cozic | Executive VP & Chief People Officer |
| Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer |
| Mr. Martin Schultz | Senior Director of Clinical Operations & Non-Independent Director |
| Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer |
| Dr. Tahamtan Ahmadi | Executive VP, Chief Medical Officer & Head of Experimental Medicines |
| Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials & Non-Independent Director |
| Mr. Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 14.0252 |
|---|---|
| Trailing PE: | 20 |
| Price-to-Book MRQ: | 2.8992 |
| Price-to-Sales TTM: | 0.7008 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2635 |